Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Bipolar Disorders
Published in: International Journal of Bipolar Disorders 1/2015

Open Access 01-12-2015 | Letter to the Editor

More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?

Author: Willem A Nolen

Published in: International Journal of Bipolar Disorders | Issue 1/2015

Login to get access

Abstract

With two recent systematic reviews and meta-analyses on the efficacy of lithium compared to placebo and other treatment options, it can now be concluded that lithium is the only drug that has been shown efficacious in the prevention of any mood episodes, manic episodes and depressive episodes in randomised trials not enriched for prior response to and tolerance of lithium. It is argued that lithium should be recommended as the single preferred first-line drug in the long-term treatment of bipolar disorder.
Literature
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1–50.
Bech P. The full story of lithium. A tribute to Mogens Schou (1918-2005). Psychother Psychosom. 2006;75(5):265–9.PubMedCrossRef
Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217–22.PubMedCrossRef
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.PubMedCrossRef
Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–9.CrossRef
National Institute for Health and Care Excellence (NICE). Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: NICE; 2006. www.​nice.​org.​uk/​CG38.
National Institute for Health and Care Excellence (NICE). The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care, updated edition. London: NICE; 2014. www.​nice.​org.​uk/​CG185.
Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disorders. 2014; Dec 20;2:15.
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–7.PubMedCrossRef
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011;72(11):1452–64.PubMedCrossRef
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.PubMedCrossRef
Metadata
Title
More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?
Author
Willem A Nolen
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Bipolar Disorders / Issue 1/2015
Electronic ISSN: 2194-7511
DOI
https://doi.org/10.1186/s40345-014-0017-6

Other articles of this Issue 1/2015

International Journal of Bipolar Disorders 1/2015 Go to the issue

Research

Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments

Research

The influence of life events on first and recurrent admissions in bipolar disorder

Research

Common use of dietary supplements for bipolar disorder: a naturalistic, self-reported study

Review

Treatment of lithium intoxication: facing the need for evidence

Short communication

Will mania survive DSM-5 and ICD-11?

Case Report

Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report